In vitro and in vivo activity of liposome-encapsulated curcumin for naturally occurring canine cancers

Sita S. Withers, Daniel York, Eric G Johnson, Sami Al-Nadaf, Katherine A Skorupski, Carlos O. Rodriguez, Jenna H Burton, Teri Guerrero, Kriste Sein, Luke Anthony Wittenburg, Robert B Rebhun

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Curcumin has well-established anti-cancer properties in vitro, however, its therapeutic potential has been hindered by its poor bioavailability. Lipocurc is a proprietary liposome-encapsulated curcumin formulation that enables intravenous delivery and has been shown to reach its highest concentration within lung tissue. The goal of this study was to characterize the anti-cancer and anti-angiogenic activity of Lipocurc in vitro, in addition to evaluating Lipocurc infusions in dogs with naturally occurring cancer. We therefore evaluated the effect of Lipocurc, relative to free curcumin, on the viability of canine osteosarcoma, melanoma and mammary carcinoma cell lines, as well as the ability of Lipocurc to inhibit endothelial cell viability, migration and tube formation. We also undertook a pilot clinical trial consisting of four weekly 8-hour Lipocurc infusions in 10 cancer-bearing dogs. Tumour cell proliferation was inhibited by curcumin at concentrations exceeding those achievable in the lung tissue of dogs. Similarly, equivalent high concentrations of Lipocurc and curcumin also inhibited endothelial cell viability, migration and tube formation. Four out of six dogs completing planned infusions of Lipocurc experienced stable disease; however, no radiographic responses were detected.

Original languageEnglish (US)
JournalVeterinary and Comparative Oncology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Curcumin
curcumin
Liposomes
Canidae
neoplasms
dogs
Dogs
Neoplasms
endothelial cells
Cell Movement
cell viability
Cell Survival
Endothelial Cells
lungs
Lung
osteosarcoma
Osteosarcoma
melanoma
breast neoplasms
Biological Availability

Keywords

  • curcumin
  • dogs
  • liposomes
  • lung
  • metastasis

ASJC Scopus subject areas

  • veterinary(all)

Cite this

@article{85adb6a245454adcb1e4ccbdef3870dc,
title = "In vitro and in vivo activity of liposome-encapsulated curcumin for naturally occurring canine cancers",
abstract = "Curcumin has well-established anti-cancer properties in vitro, however, its therapeutic potential has been hindered by its poor bioavailability. Lipocurc is a proprietary liposome-encapsulated curcumin formulation that enables intravenous delivery and has been shown to reach its highest concentration within lung tissue. The goal of this study was to characterize the anti-cancer and anti-angiogenic activity of Lipocurc in vitro, in addition to evaluating Lipocurc infusions in dogs with naturally occurring cancer. We therefore evaluated the effect of Lipocurc, relative to free curcumin, on the viability of canine osteosarcoma, melanoma and mammary carcinoma cell lines, as well as the ability of Lipocurc to inhibit endothelial cell viability, migration and tube formation. We also undertook a pilot clinical trial consisting of four weekly 8-hour Lipocurc infusions in 10 cancer-bearing dogs. Tumour cell proliferation was inhibited by curcumin at concentrations exceeding those achievable in the lung tissue of dogs. Similarly, equivalent high concentrations of Lipocurc and curcumin also inhibited endothelial cell viability, migration and tube formation. Four out of six dogs completing planned infusions of Lipocurc experienced stable disease; however, no radiographic responses were detected.",
keywords = "curcumin, dogs, liposomes, lung, metastasis",
author = "Withers, {Sita S.} and Daniel York and Johnson, {Eric G} and Sami Al-Nadaf and Skorupski, {Katherine A} and Rodriguez, {Carlos O.} and Burton, {Jenna H} and Teri Guerrero and Kriste Sein and Wittenburg, {Luke Anthony} and Rebhun, {Robert B}",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/vco.12424",
language = "English (US)",
journal = "Veterinary and Comparative Oncology",
issn = "1476-5829",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - In vitro and in vivo activity of liposome-encapsulated curcumin for naturally occurring canine cancers

AU - Withers, Sita S.

AU - York, Daniel

AU - Johnson, Eric G

AU - Al-Nadaf, Sami

AU - Skorupski, Katherine A

AU - Rodriguez, Carlos O.

AU - Burton, Jenna H

AU - Guerrero, Teri

AU - Sein, Kriste

AU - Wittenburg, Luke Anthony

AU - Rebhun, Robert B

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Curcumin has well-established anti-cancer properties in vitro, however, its therapeutic potential has been hindered by its poor bioavailability. Lipocurc is a proprietary liposome-encapsulated curcumin formulation that enables intravenous delivery and has been shown to reach its highest concentration within lung tissue. The goal of this study was to characterize the anti-cancer and anti-angiogenic activity of Lipocurc in vitro, in addition to evaluating Lipocurc infusions in dogs with naturally occurring cancer. We therefore evaluated the effect of Lipocurc, relative to free curcumin, on the viability of canine osteosarcoma, melanoma and mammary carcinoma cell lines, as well as the ability of Lipocurc to inhibit endothelial cell viability, migration and tube formation. We also undertook a pilot clinical trial consisting of four weekly 8-hour Lipocurc infusions in 10 cancer-bearing dogs. Tumour cell proliferation was inhibited by curcumin at concentrations exceeding those achievable in the lung tissue of dogs. Similarly, equivalent high concentrations of Lipocurc and curcumin also inhibited endothelial cell viability, migration and tube formation. Four out of six dogs completing planned infusions of Lipocurc experienced stable disease; however, no radiographic responses were detected.

AB - Curcumin has well-established anti-cancer properties in vitro, however, its therapeutic potential has been hindered by its poor bioavailability. Lipocurc is a proprietary liposome-encapsulated curcumin formulation that enables intravenous delivery and has been shown to reach its highest concentration within lung tissue. The goal of this study was to characterize the anti-cancer and anti-angiogenic activity of Lipocurc in vitro, in addition to evaluating Lipocurc infusions in dogs with naturally occurring cancer. We therefore evaluated the effect of Lipocurc, relative to free curcumin, on the viability of canine osteosarcoma, melanoma and mammary carcinoma cell lines, as well as the ability of Lipocurc to inhibit endothelial cell viability, migration and tube formation. We also undertook a pilot clinical trial consisting of four weekly 8-hour Lipocurc infusions in 10 cancer-bearing dogs. Tumour cell proliferation was inhibited by curcumin at concentrations exceeding those achievable in the lung tissue of dogs. Similarly, equivalent high concentrations of Lipocurc and curcumin also inhibited endothelial cell viability, migration and tube formation. Four out of six dogs completing planned infusions of Lipocurc experienced stable disease; however, no radiographic responses were detected.

KW - curcumin

KW - dogs

KW - liposomes

KW - lung

KW - metastasis

UR - http://www.scopus.com/inward/record.url?scp=85052386510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052386510&partnerID=8YFLogxK

U2 - 10.1111/vco.12424

DO - 10.1111/vco.12424

M3 - Article

C2 - 30088848

AN - SCOPUS:85052386510

JO - Veterinary and Comparative Oncology

JF - Veterinary and Comparative Oncology

SN - 1476-5829

ER -